ALCJ.PA rises 10.96% intraday on 06 Jan 2026: watch EUR 2.40 high for momentum
ALCJ.PA stock led EURONEXT top gainers on 06 Jan 2026, rising 10.96% to EUR 2.38 intraday on higher volume. The intraday range ran from EUR 2.07 to a day high of EUR 2.40 on volume 305,442, above the 50-day average of 247,199 shares. Crossject SA (ALCJ.PA) gains came amid renewed investor focus on its needle-free ZENEO platform and higher short-term momentum in the Healthcare sector in Europe.
ALCJ.PA stock intraday drivers
ALCJ.PA stock gained on 06 Jan 2026 primarily on a volume spike and favourable technical momentum. The stock opened at EUR 2.18 and traded up to EUR 2.40 as buyers picked shares above the 50-day average price of EUR 2.28. Institutional interest and mentions on sector comparison pages likely lifted sentiment, according to market chatter and Investing.com listings. For context, daily relative volume was 1.21, signalling above-average trading activity.
ALCJ.PA stock fundamentals and valuation
Crossject SA trades on EURONEXT with a market cap of EUR 123,686,305.00 and shares outstanding 51,860,086.00. Reported EPS is -0.22 and the trailing PE reads -10.84, reflecting negative earnings. Balance-sheet snapshots show a current ratio of 2.70 and cash per share EUR 0.13, providing short-term liquidity cushion. Compared with the Healthcare sector average PE of 35.26, ALCJ.PA valuation is atypical for the group, signalling higher risk and a clinical-stage company profile.
ALCJ.PA stock technicals and trading metrics
Technically, ALCJ.PA shows mixed momentum. RSI sits at 50.59, MACD histogram at 0.02, and ADX at 25.85, indicating a developing trend. Bollinger Bands middle sits near EUR 2.13 and the day high EUR 2.40 marks near-term resistance. Price averages: 50-day EUR 2.28, 200-day EUR 1.79, so the move keeps price above both averages. Traders should note the CCI at 113.18 and Stochastic %K at 94.46, both signalling short-term overbought conditions.
Meyka AI rates ALCJ.PA with a score out of 100
Meyka AI rates ALCJ.PA with a score out of 100: 69.67 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade reflects above-average short-term momentum and liquidity, offset by negative earnings and thin market capitalisation. These grades are informational only and not financial advice.
ALCJ.PA stock forecast and analyst outlook
Meyka AI’s forecast model projects a monthly target of EUR 2.00 and a yearly target of EUR 0.71 for ALCJ.PA stock. Versus the current EUR 2.38, the monthly projection implies a -15.97% move and the yearly projection implies a -70.03% move. Forecasts are model-based projections and not guarantees. Market analysts point to clinical progress for ZENEO and potential licensing deals as key upside catalysts, while trial outcomes and financing needs remain primary risk factors.
ALCJ.PA stock risks and sector context
Crossject operates in Medical – Instruments & Supplies where peers often carry higher valuations and larger market caps. ALCJ.PA faces execution risk from clinical trials, funding need risk given negative EPS, and volatility from low float. The company’s current ratio and cash per share offer short-term buffer, but its negative operating cash flow per share EUR -0.16 highlights dependence on external funding. Sector trends in Healthcare show moderate YTD gains; Crossject’s small-cap profile makes it sensitive to sector news.
Final Thoughts
ALCJ.PA stock was the intraday top gainer on 06 Jan 2026, up 10.96% to EUR 2.38 on a 305,442 volume surge. Short-term momentum is positive, with price above the 50-day and 200-day averages, but technical oscillators show overbought reads. Fundamental indicators show negative EPS -0.22 and a trailing PE -10.84, which increases risk for longer-term investors. Meyka AI’s model projects a monthly EUR 2.00 and yearly EUR 0.71 forecast, implying -15.97% and -70.03% moves versus today’s price; forecasts are model-based projections and not guarantees. Investors should weigh potential licensing or clinical wins against financing and trial risks. For traders, watch the EUR 2.40 intraday high and volume confirmation; for investors, prioritise clinical-readout clarity and funding path before adding exposure. Meyka AI provides this analysis as an AI-powered market analysis platform to help frame risk and opportunity.
FAQs
ALCJ.PA stock rose on 06 Jan 2026 driven by a volume surge to 305,442 shares, technical momentum above the 50-day average, and renewed sector attention. Market chatter referenced Crossject’s ZENEO platform and relative sector comparisons on Investing.com.
Key risks include negative EPS **-0.22**, reliance on external financing, clinical trial execution, and small-cap volatility. The company’s trailing PE is **-10.84**, reflecting losses and higher investment risk compared with larger Healthcare peers.
Meyka AI’s forecast model projects a monthly target of **EUR 2.00**, implying about **-15.97%** from today’s **EUR 2.38**. Forecasts are model-based projections and not guarantees.
Crossject SA (ALCJ.PA) is listed on **EURONEXT** in Europe and quoted in **EUR**. The stock’s market cap is approximately **EUR 123,686,305.00** and shares outstanding are **51,860,086.00**.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
